RxDoctor Payments Data

Vishnu Priya Mallipeddi

Cardiovascular Disease · Reidsville, NCNPI 1386175008

Payments from drug & device makers

$5,268in general payments, 2019–2025

Across 87 payments — averaging $60.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$2K
  • Novartis$226
  • Amgen$197
  • Inari Medical, Inc.$157
  • Novo Nordisk$153
  • plus $814 from 13 others

What the payments were for

  • Travel & lodging$2,90955%
  • Food & beverage$2,33944%
  • Education$200%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,268 in reported general payments places this provider in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$59,741
Medicare patients
492
Services billed
1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$128,761
EntrestoSacubitril/Valsartan111$80,372
XareltoRivaroxaban62$43,485
FarxigaDapagliflozin Propanediol63$36,609
BrilintaTicagrelor29$19,046
JardianceEmpagliflozin31$18,958
MounjaroTirzepatide17$18,241
Repatha SureclickEvolocumab12$13,897
Diltiazem 12hr ErDiltiazem Hcl11$2,883
Metoprolol Tartrate311$1,766
Potassium Chloride107$1,759
Rosuvastatin Calcium158$1,726
Ezetimibe117$1,632
Atorvastatin Calcium123$1,423
Ranolazine ErRanolazine31$1,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$128,761180 claims
NovartisEntresto$226$80,372111 claims
AstraZenecaFarxiga, Brilinta$26$55,65592 claims
Johnson & JohnsonXarelto$35$43,48562 claims
Boehringer IngelheimJardiance$19$18,95831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Reidsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →